2026-04-02 20:23:39
PharmaCyte Biotech, Inc. Increases Share Availability in Equity Incentive Plan by 2 Million Shares
Expected Stock impact: Slightly Positive
On April 2, 2026, PharmaCyte Biotech, Inc. (the "Company") filed a Form 8-K with the Securities and Exchange Commission (SEC) detailing the outcomes of its annual meeting of stockholders held on March 30, 2026. A significant decision made during this meeting was the approval of an amendment to the Company's 2022 Equity Incentive Plan. This amendment allows for an increase in the number of shares of the Company's common stock available for the grant of awards by 2,000,000 shares. This change is expected to enhance the Company's ability to attract and retain talent by providing additional equity incentives to employees and directors. The amendment reflects the Company's commitment to incentivizing its workforce and aligning their interests with those of shareholders. The meeting saw approximately 55.08% of the outstanding shares represented, indicating a strong engagement from stockholders. The approval of this amendment is seen as a positive step for the Company, potentially leading to improved operational execution and strategic growth as it continues to develop its business in the biotech sector. The full details of the 2022 Equity Incentive Plan, as amended, can be found in Exhibit 10.1 attached to the filing.
